Ilmarinen Mutual Pension Insurance Co cut its holdings in shares of Illumina, Inc. (NASDAQ:ILMN – Free Report) by 23.2% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,900 shares of the life sciences company’s stock after selling 5,100 shares during the quarter. Ilmarinen Mutual Pension Insurance Co’s holdings in Illumina were worth $4,625,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the business. Resona Asset Management Co. Ltd. boosted its holdings in Illumina by 3.2% in the 3rd quarter. Resona Asset Management Co. Ltd. now owns 40,288 shares of the life sciences company’s stock worth $11,011,000 after buying an additional 1,267 shares during the period. E Fund Management Hong Kong Co. Ltd. purchased a new position in Illumina in the 3rd quarter valued at approximately $31,000. Advisors Asset Management Inc. bought a new stake in Illumina during the 3rd quarter valued at $5,555,000. Private Wealth Asset Management LLC bought a new stake in Illumina during the 3rd quarter valued at $1,668,000. Finally, Private Advisor Group LLC bought a new stake in Illumina during the 3rd quarter valued at $510,000. 89.42% of the stock is owned by hedge funds and other institutional investors.
Illumina Price Performance
NASDAQ:ILMN opened at $192.82 on Friday. Illumina, Inc. has a 52-week low of $112.65 and a 52-week high of $309.35. The stock has a fifty day moving average of $248.27 and a 200 day moving average of $181.05. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.05 and a current ratio of 2.63. The firm has a market capitalization of $29.15 billion, a price-to-earnings ratio of 33.19, a P/E/G ratio of 2.62 and a beta of 1.46.
Illumina (NASDAQ:ILMN – Get Free Report) last announced its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The business had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the prior year, the company earned $1.34 EPS. The company’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, research analysts expect that Illumina, Inc. will post 5.43 EPS for the current fiscal year.
Insider Activity at Illumina
In related news, Director Keith Meister sold 231,433 shares of the company’s stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $238.52, for a total value of $55,201,399.16. Following the transaction, the director directly owned 538,917 shares in the company, valued at approximately $128,542,482.84. This represents a 30.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 1,201,292 shares of company stock worth $270,151,290 over the last ninety days. 2.90% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
A number of equities analysts have recently commented on ILMN shares. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Citigroup boosted their price objective on Illumina from $113.00 to $210.00 and gave the company a “sell” rating in a research note on Monday, November 2nd. Piper Sandler increased their price objective on Illumina from $225.00 to $305.00 and gave the stock an “overweight” rating in a report on Monday, September 28th. Weiss Ratings cut Illumina from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday. Finally, Argus raised their target price on Illumina from $180.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, September 3rd. Nine research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $243.72.
View Our Latest Analysis on Illumina
Recent Illumina Headlines
Investors following ILMN have been watching these headlines:
- Positive Sentiment: Illumina’s BioInsight AI Lab won the 2026 Virtual Cell Challenge using its Billion Cell Atlas and CellularAI algorithm. The result highlights the company’s data and AI capabilities, although the financial impact is not yet clear. Illumina Wins Virtual Cell Challenge, Powered by Billion Cell Atlas
- Positive Sentiment: A proposed Senate bill would clarify Medicaid coverage for whole-genome and whole-exome sequencing for certain children. If enacted, broader coverage could support demand for sequencing, but the proposal remains early-stage. Genomic Answers for Children’s Health Act of 2026
- Negative Sentiment: Voluntary Class II recalls linked to cybersecurity vulnerabilities in several diagnostic sequencing instruments have heightened concerns about operational risk and data integrity. The report also notes recent weakness in the shares, adding to near-term pressure. Is Illumina Undervalued Following Its Cybersecurity Recalls?
Illumina Company Profile
Illumina, Inc. develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data. The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.
Recommended Stories
- Five stocks we like better than Illumina
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN – Free Report).
Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.
